Compare Elder Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA CIPLA ELDER PHARMA/
CIPLA
 
P/E (TTM) x -0.2 32.2 - View Chart
P/BV x 0.1 4.6 2.2% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ELDER PHARMA   CIPLA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
CIPLA
Mar-20
ELDER PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs380586 64.9%   
Low Rs188357 52.7%   
Sales per share (Unadj.) Rs491.2207.0 237.2%  
Earnings per share (Unadj.) Rs-3.218.6 -17.1%  
Cash flow per share (Unadj.) Rs14.433.2 43.4%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs376.5195.5 192.6%  
Shares outstanding (eoy) m20.54806.35 2.5%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x0.62.3 25.4%   
Avg P/E ratio x-89.325.3 -352.3%  
P/CF ratio (eoy) x19.714.2 138.7%  
Price / Book Value ratio x0.82.4 31.3%  
Dividend payout %021.5 0.0%   
Avg Mkt Cap Rs m5,833379,912 1.5%   
No. of employees `000NA25.8 0.0%   
Total wages/salary Rs m2,17930,270 7.2%   
Avg. sales/employee Rs ThNM6,459.6-  
Avg. wages/employee Rs ThNM1,171.2-  
Avg. net profit/employee Rs ThNM580.2-  
INCOME DATA
Net Sales Rs m10,089166,949 6.0%  
Other income Rs m2573,442 7.5%   
Total revenues Rs m10,346170,391 6.1%   
Gross profit Rs m-79232,060 -2.5%  
Depreciation Rs m36111,747 3.1%   
Interest Rs m2,7561,974 139.7%   
Profit before tax Rs m-3,65321,782 -16.8%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1256,312 2.0%   
Profit after tax Rs m-6514,995 -0.4%  
Gross profit margin %-7.819.2 -40.9%  
Effective tax rate %-3.429.0 -11.8%   
Net profit margin %-0.69.0 -7.2%  
BALANCE SHEET DATA
Current assets Rs m9,240117,038 7.9%   
Current liabilities Rs m9,99843,931 22.8%   
Net working cap to sales %-7.543.8 -17.1%  
Current ratio x0.92.7 34.7%  
Inventory Days Days4696 48.4%  
Debtors Days Days6085 70.5%  
Net fixed assets Rs m10,124107,424 9.4%   
Share capital Rs m2061,613 12.8%   
"Free" reserves Rs m5,582156,018 3.6%   
Net worth Rs m7,734157,630 4.9%   
Long term debt Rs m4,88923,693 20.6%   
Total assets Rs m22,882236,626 9.7%  
Interest coverage x-0.312.0 -2.7%   
Debt to equity ratio x0.60.2 420.6%  
Sales to assets ratio x0.40.7 62.5%   
Return on assets %11.87.2 164.0%  
Return on equity %-0.89.5 -8.9%  
Return on capital %22.312.8 173.8%  
Exports to sales %3.033.0 9.2%   
Imports to sales %0.40-   
Exports (fob) Rs m30755,175 0.6%   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30756,036 0.5%   
Fx outflow Rs m1256,764 1.9%   
Net fx Rs m18149,272 0.4%   
CASH FLOW
From Operations Rs m11,75430,685 38.3%  
From Investments Rs m-5611,040 -53.9%  
From Financial Activity Rs m-6,762-29,488 22.9%  
Net Cashflow Rs m4,4322,340 189.4%  

Share Holding

Indian Promoters % 39.6 16.0 247.5%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 7.5 12.2 61.5%  
FIIs % 16.8 23.7 70.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 36.1 26.2 137.8%  
Shareholders   16,479 161,166 10.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  FULFORD INDIA  ALKEM LABORATORIES  DIVIS LABORATORIES  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; JSW Steel and Hindalco Among Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS